LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Wach trotz Narkose

    Lanotte, Livia

    intensiv

    2015  Volume 23, Issue 05, Page(s) 277–283

    Abstract: Stellen Sie sich vor, Sie werden operiert und wachen trotz Narkose mitten im Eingriff auf – unfähig zu sprechen oder anderweitig zu reagieren. Diese „intraoperative Wachheit“ kommt bei mehr Patienten vor als bisher ... ...

    Abstract Stellen Sie sich vor, Sie werden operiert und wachen trotz Narkose mitten im Eingriff auf – unfähig zu sprechen oder anderweitig zu reagieren. Diese „intraoperative Wachheit“ kommt bei mehr Patienten vor als bisher angenommen und kann schlimme postoperative Folgen haben. Grund genug für Livia Lanotte, sich intensiver mit dem Thema auseinanderzusetzen. Ihre Facharbeit hat den
    3. Platz beim Thieme intensiv-Pflegepreis 2014: belegt. Kernstück ist ein eigens entwickelter Pathway, der hilft, das Risiko einer Awareness besser einzuschätzen.
    Language German
    Publishing date 2015-09-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2072493-7
    ISSN 1439-3840 ; 0942-6035
    ISSN (online) 1439-3840
    ISSN 0942-6035
    DOI 10.1055/s-0041-105106
    Database Thieme publisher's database

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Wach trotz Narkose

    Lanotte, Livia

    Intensiv: Fachzeitschrift für Intensivpflege und Anästhesie

    2015  Volume 23, Issue 5, Page(s) 277–283

    Abstract: Stellen Sie sich vor, Sie werden operiert und wachen trotz Narkose mitten im Eingriff auf – unfähig zu sprechen oder anderweitig zu reagieren. Diese „intraoperative Wachheit“ kommt bei mehr Patienten vor als bisher angenommen und kann schlimme ... ...

    Abstract Stellen Sie sich vor, Sie werden operiert und wachen trotz Narkose mitten im Eingriff auf – unfähig zu sprechen oder anderweitig zu reagieren. Diese „intraoperative Wachheit“ kommt bei mehr Patienten vor als bisher angenommen und kann schlimme postoperative Folgen haben. Grund genug für Livia Lanotte, sich intensiver mit dem Thema auseinanderzusetzen. Ihre Facharbeit hat den 3. Platz beim Thieme intensiv-Pflegepreis 2014 belegt. Kernstück ist ein eigens entwickelter Pathway, der hilft, das Risiko einer Awareness besser einzuschätzen.
    Keywords Anästhesie ; Awareness
    Language German
    Document type Article
    ZDB-ID 1148969-8
    ISSN 0942-6035
    ISSN 0942-6035
    Database bibnet.org

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3626: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.

    Demuth, Stanislas / Bogdan, Thomas / Kremer, Laurent / Lanotte, Livia / Collongues, Nicolas / de Seze, Jérôme / Bigaut, Kévin

    Journal of neurology

    2022  Volume 269, Issue 6, Page(s) 3347–3350

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Immunotherapy ; Infliximab/therapeutic use ; Susac Syndrome/diagnostic imaging ; Susac Syndrome/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; Infliximab (B72HH48FLU) ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2022-01-19
    Publishing country Germany
    Document type Case Reports ; Letter
    ZDB-ID 187050-6
    ISSN 1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    ISSN (online) 1432-1459
    ISSN 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    DOI 10.1007/s00415-021-10922-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.40: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.

    Moreau, Augustin / Kolitsi, Ioanna / Kremer, Laurent / Fleury, Marie / Lanotte, Livia / Sellal, François / Gaultier, Claude / Ahle, Guido / Courtois, Sylvie / Fickl, Andreas / Mostoufizadeh, Sohrab / Dentel, Christel / Collongues, Nicolas / de Seze, Jérôme / Bigaut, Kévin

    Multiple sclerosis and related disorders

    2023  Volume 79, Page(s) 104942

    Abstract: Background: Pediatric forms of multiple sclerosis are more active than those in adults. Yet, the effectiveness of different therapeutic approaches is not well studied in this population. Our objective was to compare the effectiveness of the early use of ...

    Abstract Background: Pediatric forms of multiple sclerosis are more active than those in adults. Yet, the effectiveness of different therapeutic approaches is not well studied in this population. Our objective was to compare the effectiveness of the early use of high efficacy therapies (HETs) with the effectiveness of moderate efficacy therapies (METs) in children with MS.
    Methods: This observational study included patients diagnosed with pediatric MS, at 4 hospital centers in France, during a 10-year period. METs included: interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide; HETs included: fingolimod, natalizumab, ocrelizumab, alemtuzumab. The primary endpoint was the occurrence of a new relapse, the secondary endpoint was EDSS worsening.
    Results: Sixty-four patients were included in the analysis (80% women; mean age 15.5 years, 81% treated with MET) with a median follow-up of 22.5 months. At baseline, 52 patients were on MET (interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide) and 12 patients were on HET (natalizumab, ocrelizumab). The cumulative probability of being relapse-free at 6.5 years was 23.3% on MET, vs 90.9% on HET (p = 0.013). The cumulative probability of no EDSS worsening did not differ between the 2 groups.
    Conclusion: Patients starting with METs had much higher clinical disease activity than those starting early with HETs. Rapid initiation of more aggressive treatment may allow better disease control; however, the data on EDSS worsening are not conclusive.
    MeSH term(s) Adolescent ; Child ; Female ; Humans ; Male ; Dimethyl Fumarate/therapeutic use ; Fingolimod Hydrochloride/therapeutic use ; Glatiramer Acetate/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Interferon beta-1a/therapeutic use ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab/therapeutic use ; Recurrence
    Chemical Substances Dimethyl Fumarate (FO2303MNI2) ; Fingolimod Hydrochloride (G926EC510T) ; Glatiramer Acetate (5M691HL4BO) ; Immunosuppressive Agents ; Interferon beta-1a (XRO4566Q4R) ; Natalizumab ; teriflunomide (1C058IKG3B)
    Language English
    Publishing date 2023-08-13
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2023.104942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.

    Bigaut, Kévin / Kremer, Laurent / Fabacher, Thibaut / Lanotte, Livia / Fleury, Marie-Celine / Collongues, Nicolas / de Seze, Jerome

    Neurology(R) neuroimmunology & neuroinflammation

    2021  Volume 8, Issue 5

    Abstract: Objective: To compare the humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with multiple sclerosis (MS) receiving different disease-modifying treatments (DMTs).: Methods: Patients with MS with ... ...

    Abstract Objective: To compare the humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with multiple sclerosis (MS) receiving different disease-modifying treatments (DMTs).
    Methods: Patients with MS with coronavirus disease 2019 (COVID-19) and available anti-SARS-CoV-2 serology were included. The primary endpoint was the anti-SARS-CoV-2 immunoglobulin G (IgG) index. The multivariate analysis was adjusted for COVID-19 severity, SARS-CoV-2 PCR result, and the time between COVID-19 onset and the serology.
    Results: We included 61 patients with available IgG index. The IgG index was lower in patients with fingolimod or anti-CD20 monoclonal antibodies compared with patients without treatment (
    Conclusions: Humoral response after COVID-19 was lower in patients with MS with fingolimod or anti-CD20 mAb. These patients could therefore be at risk of recurrent infection and could benefit from anti-SARS-CoV-2 vaccination. The humoral response after vaccination and the delay before vaccination need to be evaluated.
    Classification of evidence: This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs.
    MeSH term(s) Adult ; Antibodies, Viral/blood ; Antibodies, Viral/drug effects ; COVID-19/immunology ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/immunology ; SARS-CoV-2/immunology
    Chemical Substances Antibodies, Viral ; Immunosuppressive Agents
    Language English
    Publishing date 2021-07-28
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 2767740-0
    ISSN 2332-7812 ; 2332-7812
    ISSN (online) 2332-7812
    ISSN 2332-7812
    DOI 10.1212/NXI.0000000000001055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic.

    Coste, Thibault / Hervé, Dominique / Neau, Jean Philippe / Jouvent, Eric / Ba, Fatoumata / Bergametti, Françoise / Lamy, Matthias / Cogez, Julien / Derache, Nathalie / Schneckenburger, Romain / Grelet, Maude / Gollion, Cédric / Lanotte, Livia / Lauer, Valérie / Layet, Valérie / Urbanczyk, Cédric / Didic, Mira / Raynouard, Igor / Delaval, Laure /
    Dassa, Jérémie / Florea, Alexandru / Badiu, Carmen / Nguyen, Karine / Tournier-Lasserve, Elisabeth

    Brain : a journal of neurology

    2021  Volume 144, Issue 9, Page(s) 2616–2624

    Abstract: Heterozygous missense HTRA1 mutations have been associated with an autosomal dominant cerebral small vessel disease (CSVD) whereas the pathogenicity of heterozygous HTRA1 stop codon variants is unclear. We performed a targeted high throughput sequencing ... ...

    Abstract Heterozygous missense HTRA1 mutations have been associated with an autosomal dominant cerebral small vessel disease (CSVD) whereas the pathogenicity of heterozygous HTRA1 stop codon variants is unclear. We performed a targeted high throughput sequencing of all known CSVD genes, including HTRA1, in 3853 unrelated consecutive CSVD patients referred for molecular diagnosis. The frequency of heterozygous HTRA1 mutations leading to a premature stop codon in this patient cohort was compared with their frequency in large control databases. An analysis of HTRA1 mRNA was performed in several stop codon carrier patients. Clinical and neuroimaging features were characterized in all probands. Twenty unrelated patients carrying a heterozygous HTRA1 variant leading to a premature stop codon were identified. A highly significant difference was observed when comparing our patient cohort with control databases: gnomAD v3.1.1 [P = 3.12 × 10-17, odds ratio (OR) = 21.9], TOPMed freeze 5 (P = 7.6 × 10-18, OR = 27.1) and 1000 Genomes (P = 1.5 × 10-5). Messenger RNA analysis performed in eight patients showed a degradation of the mutated allele strongly suggesting a haploinsufficiency. Clinical and neuroimaging features are similar to those previously reported in heterozygous missense mutation carriers, except for penetrance, which seems lower. Altogether, our findings strongly suggest that heterozygous HTRA1 stop codons are pathogenic through a haploinsufficiency mechanism. Future work will help to estimate their penetrance, an important information for genetic counselling.
    MeSH term(s) Aged ; Brain/diagnostic imaging ; Codon, Nonsense/genetics ; Female ; Frameshift Mutation/genetics ; Heterozygote ; High-Temperature Requirement A Serine Peptidase 1/genetics ; Humans ; Male ; Middle Aged ; Pedigree
    Chemical Substances Codon, Nonsense ; High-Temperature Requirement A Serine Peptidase 1 (EC 3.4.21.-) ; HTRA1 protein, human (EC 3.4.21.-)
    Language English
    Publishing date 2021-07-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awab271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top